PRESS RELEASE

Biom’up completes its Board of Directors with the nomination of Dr. Peter Byloos to support its international growth

Dr. Byloos possesses solid experience in the healthcare sector. Currently CEO of Optegra Eye Health Care, a UK based eye treatment company, he previously served as CEO and President of Handicare, the specialized Norwegian equipment provider for the elderly and disabled and has occupied several International Leadership positions with CR…

READ

Biom’up present at the 8 th Strategic Council of Health Industries hosted by France’s Prime Minister

An illustration of Biom’up’s first achievements and growing position in international markets Significant growth of the number of U.S. hospitals undergoing a medical-economic evaluation of HEMOBLASTTM Bellows A strengthened sales force in the United States

READ

Biom’up obtains CE Mark for its HEMOBLASTTM Bellows Laparoscopic Applicator

An additional device designed to deliver the HEMOBLAST Bellows powder in minimally-invasive procedures Biom’up ready to address a new European market segment where traditional hemostatic products are generally difficult to use or unusable Yet another important milestone enabling Biom’up to address a new market of approximately 500,000 surgeries per year…

READ

Caution: Federal law restricts this device to sale on or by the order of a physician. The trademark of HEMOBLAST™ Bellows and SPOT GRADE™ are the property of Biom’up. The trademarks of the products listed herein are trademarks of their respective manufacturer. Please refer to the Instructions for Use accompanying each device for further information. The presentation contains pictures owned by third party and remains their property.
E-MR-318-V1
HEMOBLAST™ Bellows Hemostatic Agent [instructions for use: E-MR-217-V6]